| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 03/11/2004 | DE10240064A1 Use of chemokine receptor antagonist for treatment of cancer and inhibition of metastasis, functions as ligand for the CXCR4 receptor |
| 03/11/2004 | DE10238697A1 New peptaibol peptide compounds having high alpha-aminoisobutyric acid content, useful for treating neurological diseases such as schizophrenia, obtained by culturing Trichoderma strain |
| 03/11/2004 | DE10237317A1 Enzymhaltige Zusammensetzung, Verfahren zu deren Herstellung und deren Verwendung An enzyme-containing composition, to processes for their preparation and their use |
| 03/11/2004 | CA2537158A1 Cxcr4 antagonist and use thereof |
| 03/11/2004 | CA2536604A1 Plant extracts for treatment of angiogenesis and metastasis |
| 03/11/2004 | CA2497597A1 Methods for identifying subjects at risk of melanoma and treatments |
| 03/11/2004 | CA2497281A1 Novel depsipeptide compound |
| 03/11/2004 | CA2497159A1 Glycopeptide antibiotic and semisynthetic derivatives thereof and their use as antiviral agents |
| 03/11/2004 | CA2497151A1 Methods for up-regulating antigen expression in tumors |
| 03/11/2004 | CA2497136A1 Buccal, polar or non-polar spray or capsule containing drugs for treating an infectious disease or cancer |
| 03/11/2004 | CA2497121A1 Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| 03/11/2004 | CA2497116A1 Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma |
| 03/11/2004 | CA2497114A1 Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders |
| 03/11/2004 | CA2497112A1 Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| 03/11/2004 | CA2497086A1 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 03/11/2004 | CA2497048A1 Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure |
| 03/11/2004 | CA2497047A1 Adzymes and uses thereof |
| 03/11/2004 | CA2496925A1 Achaete-scute like-2 polypeptides and encoding nucleic acids and methods for the diagnosis and treatment of tumor |
| 03/11/2004 | CA2496904A1 Genetic suppression and replacement |
| 03/11/2004 | CA2496885A1 Method of diagnosing colon and gastric cancers |
| 03/11/2004 | CA2496820A1 Ocular gene therapy |
| 03/11/2004 | CA2496795A1 Compositions and methods for treating cardiovascular disease |
| 03/11/2004 | CA2496789A1 Methods for preserving organs and tissues |
| 03/11/2004 | CA2496772A1 Protein tyrosine phosphatase inhibitors |
| 03/11/2004 | CA2496769A1 Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| 03/11/2004 | CA2496745A1 Method of degrading transcriptional factors of saccharometabolism-associated gene, method of inhibiting the degradation and degradation inhibitor |
| 03/11/2004 | CA2496692A1 Thymus-based tolerogenic approaches for type i diabetes |
| 03/11/2004 | CA2496634A1 Modulators of tnf-alpha and il-1 cell surface receptor activity |
| 03/11/2004 | CA2496581A1 The use of erythopoieitin in the treatment of disturbances of iron distribution in diabetes |
| 03/11/2004 | CA2496577A1 Combination therapy for treatment of fibrotic disorders |
| 03/11/2004 | CA2496547A1 Use of apoptosis inducing agents in the preparation of a medicament for the treatment of liver diseases |
| 03/11/2004 | CA2496447A1 Amelioration of effects of cigarette smoke |
| 03/11/2004 | CA2496314A1 Methods of treating idiopathic pulmonary fibrosis |
| 03/11/2004 | CA2495882A1 Agents and methods for enhancing bone formation |
| 03/11/2004 | CA2495295A1 Group b streptococcal phage lysin |
| 03/11/2004 | CA2495225A1 Beta-2 microglobulin (b2m) and b2m related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation |
| 03/11/2004 | CA2495210A1 Modified transferrin fusion proteins |
| 03/11/2004 | CA2495207A1 Modified transferin-antibody fusion proteins |
| 03/11/2004 | CA2495072A1 Use of protein kinase n beta |
| 03/11/2004 | CA2494981A1 Production of multimeric fusion proteins using a c4bp scaffold |
| 03/11/2004 | CA2493199A1 Peroxynitrite rearrangement catalysts used for the treatment or prophylaxis of diseases caused by peroxynitrite-mediated reactions |
| 03/11/2004 | CA2492324A1 Method for isolating subpopulations of proteins that engage in protein-protein interactions |
| 03/10/2004 | EP1396542A2 Novel P-selectin ligand protein |
| 03/10/2004 | EP1396541A2 Multimeric forms of members of the steroid/thyroid superfamily of receptors |
| 03/10/2004 | EP1396539A1 Human-type anti-blood coagulation factor viii antibody |
| 03/10/2004 | EP1396492A1 Prodrug of an ice inhibitor |
| 03/10/2004 | EP1396272A1 Insoluble Insulin Compositions for Controlling Blood Glucose |
| 03/10/2004 | EP1396270A1 Boronic acid salts and use thereof in the preparation of medicaments for treating thrombosis |
| 03/10/2004 | EP1396269A1 Boronic acid salts of multivalent metals used in the preparation of a medicament for treating thrombosis |
| 03/10/2004 | EP1395828A2 Proteins and genes for diagnosis and treatment of erbb2-related cancer |
| 03/10/2004 | EP1395684A2 New polynucleotides and polypeptides of the ifnalpha-7 gene |
| 03/10/2004 | EP1395665A1 Production of the lantibiotic cinnamycin with genes isolated from streptomyces cinnamoneus |
| 03/10/2004 | EP1395658A2 Nucleic acid and protein sequences of bovine epidermal growth factor |
| 03/10/2004 | EP1395657A2 Receptor for bacillus anthracis toxin |
| 03/10/2004 | EP1395656A2 Human drug metabolizing enzymes |
| 03/10/2004 | EP1395654A1 Regulation of human zinc carboxypeptidase b-like protein |
| 03/10/2004 | EP1395648A2 Methods for binding acma-type protein anchor fusions to cell-wall material of micro-organisms |
| 03/10/2004 | EP1395610A2 Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell and hematopoietic progenitor cell, and dna coding for the same |
| 03/10/2004 | EP1395609A2 Hypoxia inducible factors and uses thereof for inducing angiogenesis and improving muscular functions |
| 03/10/2004 | EP1395606A1 Pyrrolidin-2-one derivatives as inhibitors of factor xa |
| 03/10/2004 | EP1395605A2 Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors |
| 03/10/2004 | EP1395602A2 Novel human potassium channel beta subunit |
| 03/10/2004 | EP1395571A1 Compounds and methods for the treatment or prevention of flavivirus infections |
| 03/10/2004 | EP1395301A1 Crosslinkable macromers |
| 03/10/2004 | EP1395294A2 Pulmonary administration of chemically modified insulin |
| 03/10/2004 | EP1395286A2 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
| 03/10/2004 | EP1395285A2 Reagents and methods for modulating dkk-mediated interactions |
| 03/10/2004 | EP1395281A1 Recombinant mhc molecules useful for manipulation of antigen-specific t-cells |
| 03/10/2004 | EP1395280A1 Composition and methods for affecting metallocorrinoid uptake |
| 03/10/2004 | EP1395279A2 Use of neublastin polypeptides for treating neuropathic pain |
| 03/10/2004 | EP1395278A2 Ocular tear growth factor-like protein |
| 03/10/2004 | EP1395277A1 The use of a gatran for the manufacture of a medicament for the treatment of pulmonary fibrosis |
| 03/10/2004 | EP1395276A1 Structurally modified peptides and uses thereof |
| 03/10/2004 | EP1395275A2 Beta-secretase substrates and uses thereof |
| 03/10/2004 | EP1395274A2 Compositions and methods for inhibiting metastasis |
| 03/10/2004 | EP1395273A1 Targeted delivery of drugs for the treatment of viral infections |
| 03/10/2004 | EP1395272A1 Method and compositions for inhibiting thrombin-induced coagulation |
| 03/10/2004 | EP1395270A1 Use of phyllanthus constituents for treating or preventing infections caused by hepatit |
| 03/10/2004 | EP1395264A2 Targeted delivery of drugs for the treatment of parasitic infections |
| 03/10/2004 | EP1395256A2 Prodrugs via acylation with cinnamate |
| 03/10/2004 | EP1395255A2 Cddo-compounds and combination therapies thereof |
| 03/10/2004 | EP1395240A1 Modification of the sustained release profile |
| 03/10/2004 | EP1395227A2 Methods and compounds for the diagnosis of inflammatory disease and identification of pharmacological agents useful in the treatment of inflammatory disease |
| 03/10/2004 | EP1234043B1 Constructs for delivery of therapeutic agents to neuronal cells |
| 03/10/2004 | EP1004674B1 Human adamts-1 protein, gene coding for the same, pharmaceutical composition, and method for immunologically assaying human adamts-1 protein |
| 03/10/2004 | EP0885011B1 Diagnosis of autoimmune diseases of the inner ear based on the detection of myelin protein p zero |
| 03/10/2004 | EP0868198B1 FCepsilon-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES, A METHOD FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| 03/10/2004 | EP0820300B1 Controlled release biodegradable nanoparticles containing insulin |
| 03/10/2004 | EP0769955B1 Non-antigenic amine derived polymers and polymer conjugates |
| 03/10/2004 | CN1481504A Screening assay for antagonists of human leukocyte receptors |
| 03/10/2004 | CN1481438A Method for preparing vitamin K-dependence protein |
| 03/10/2004 | CN1481390A Immunomodulatory peptidesderived from heat shock proteins and uses thereof |
| 03/10/2004 | CN1481373A 1,5-benzothiazepines compounds and its use as antilipemic agent |
| 03/10/2004 | CN1481367A Imidazole and benzimiddzole caspase inhibitors and uses thereof |
| 03/10/2004 | CN1481253A Drugs and foods improving quality of life and process for producng same |
| 03/10/2004 | CN1481252A Stabilized Inteferon compsns |
| 03/10/2004 | CN1481251A Combined method for treating viral infections |
| 03/10/2004 | CN1481236A Aerogel powder comprising therapeutic agents |
| 03/10/2004 | CN1481080A Method for lowering electromagnetic energy absorptivity of wireless communication equipment from human body |
| 03/10/2004 | CN1480466A Interfusion protein possessing dual functions of thrombolysis and anticoagulation as well as its application |